Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 19:40:106-108.
doi: 10.1016/j.jdcr.2023.08.005. eCollection 2023 Oct.

Discoid lupus erythematosus of the nail treated with thalidomide

Taylor Harp  1 , Michael J Woodbury  2 , Joseph F Merola  3
Affiliations
Case Reports

Discoid lupus erythematosus of the nail treated with thalidomide

Taylor Harp et al. JAAD Case Rep. .
No abstract available

Keywords: autoimmune disorder; cutaneous lupus erythematosus; discoid lupus erythematosus; nail disease; onychodystrophy; thalidomide.

PubMed Disclaimer

Conflict of interest statement

JFM is a consultant and/or investigator for Merck, Abbvie, Dermavant, Eli, Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma.

Figures

Fig 1
Fig 1
A 59-year-old woman with a 13-year history of systemic lupus erythematosus (SLE) with biopsy-proven discoid and tumid lupus erythematosus of the face and scalp with recalcitrant onychodystrophy. November 2016, Discoid lupus erythematosus at the proximal nailfold with resultant onychodystrophy, subungual thickening, onychauxis, and atrophic scarring on the third, fourth, and fifth digits of the left hand. February 2017, New nail involvement of the second digit after 5 months of treatment with thalidomide 50 mg 3 times weekly. November 2017, Index and small fingers with intact nail plates and minimal erythema with remarkable improvement in nail disease after increasing the dose of thalidomide to 50 mg 5 times weekly and using as-needed topical corticosteroids.
See this image and copyright information in PMC

References

    1. Durosaro O., Davis M.D.P., Reed K.B., et al. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009;145(3):249–253. doi: 10.1001/archdermatol.2009.21. - DOI - PMC - PubMed
    1. Navarro-Triviño F.J., Ruiz-Villaverde R. Chronic Discoid Lupus: An uncommon cause of nail atrophy. Sultan Qaboos Univ Med J. 2018;18(3):e411–e412. doi: 10.18295/squmj.2018.18.03.029. - DOI - PMC - PubMed
    1. Richert B., André J., Bourguignon R., De La Brassinne M. Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties. J Eur Acad Dermatol Venereol. 2004;18(6):728–730. doi: 10.1111/j.1468-3083.2004.01068.x. - DOI - PubMed
    1. Furst D.E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5(suppl 1):S11–S15. - PubMed
    1. Cortés-Hernández J., Torres-Salido M., Castro-Marrero J., et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166(3):616–623. doi: 10.1111/j.1365-2133.2011.10693.x. - DOI - PubMed

Publication types

LinkOut - more resources